Skip to content

Trial Summary

The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs).

Acronym:

NABNEC

ACTRN/NCT /ethics:

ACTRN12616000958482; Ethics 163.17

Scientific title:

A randomised phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.

Sponsor / Cooperative group:

Australasian Gastro-Intestinal Trials Group (AGITG)

Trial & Patient Characteristics

Cancer TypeNeuroendocrine
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2016-08-19
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting